My husband, Alex, said that economy needs a revolutionary technology, like automobiles, computers, internet, or mobile phones, to jolt us out of this depression. I am hopeful that something will come along soon.
Last week, ASU made an announcement regarding a major breakthrough at Dr. Roy Curtiss' lab at the BioDesign at ASU. Along with his post-doc, Xinyao Liu, Dr. Curtiss has been able to genetically modify cyanobacteria to release fatty acids into the water when CO2 is removed from their environment. This would mean less cost in processing the bacteria for the fats that will be used as fuel.
http://asunews.asu.edu/20110526_biofuelprocess
Though it might be a while before this particular technology becomes commercially viable, I am holding out hope that biofuels may be the technology that will revolutionize the way we live and will be what Arizona needs to grow our economy.
Showing posts with label Arizona. Show all posts
Showing posts with label Arizona. Show all posts
Tuesday, June 7, 2011
Sunday, June 5, 2011
Celgene - company to watch
At the end of June 2010, Celgene bought Abraxis Bioscience located here in Phoenix, Arizona for $2.9 billion. This was a huge deal for biotech/pharma industry in Arizona. Yesterday, Celgene announced the final results from a phase III study of ABRAXANE (acquired through Abaxis' aquisition), a drug in combination with carboplatin for patients with advanced non-small cell lung cancer (NSCLC) at the 2011's American Society of Clinical Oncology (ASCO) meeting. Though Abraxane doesn't significantly improve progession-free survival, Celgene still plans to submit a sNDA (supplemental New Drug Application) for first-line treatment of patients with advanced NSCLC.
So, why watch Celgene? For one thing, Celgene has 25 other drugs in late phase clinical trials. Most importantly, the purchase of Abraxis also gave Celgene the technology behind Abraxane, nab-driven chemotherapy. Added to this, Celgene's Phoenix location is hiring.
http://www.celgene.com/careers/pharmaceutical-us-job-openings.aspx
There are twelve positions listed since mid April, including a director of plant engineering.
The only question is: would there be skilled workers to fill these positions and support Celgene's clean lab and tight QC environment?
So, why watch Celgene? For one thing, Celgene has 25 other drugs in late phase clinical trials. Most importantly, the purchase of Abraxis also gave Celgene the technology behind Abraxane, nab-driven chemotherapy. Added to this, Celgene's Phoenix location is hiring.
http://www.celgene.com/careers/pharmaceutical-us-job-openings.aspx
There are twelve positions listed since mid April, including a director of plant engineering.
The only question is: would there be skilled workers to fill these positions and support Celgene's clean lab and tight QC environment?
Subscribe to:
Posts (Atom)